Heart Transplant Rejection
📧 Sign up to get email alerts when something new happens for Heart Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
FDA approves Accord Healthcare's supplemental application for generic Mycophenolate mofetil. The approval supports continued use for prevent…
-
FDA label_change · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for Mycophenolate mofetil from Endo USA, Inc., updating the drug's labeling.
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Mycophenolate mofetil from Aurobindo Pharma Limited, allowing the generic product for use in pre…
-
FDA approval · 2024-08-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CellCept (mycophenolate mofetil hydrochloride) submitted by Genentech to update the label.
-
FDA approval · 2024-08-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CellCept (mycophenolate mofetil) submitted by Genentech, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for Mycophenolate mofetil from Meitheal Pharmaceuticals Inc., confirming the generic product's appro…
-
FDA approval · 2024-08-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved Genentech's supplemental application for CELLCEPT (mycophenolate mofetil), resulting in an approved update to the product label…
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for mycophenolate mofetil from Lannett Company, authorizing a generic version under ANDA 214525.
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited under ANDA 212087.
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy [NA]
A completed clinical trial evaluating extracorporeal photopheresis for cardiac allograft vasculopathy and heart transplant rejection.
-
FDA approval · 2024-08-09FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Accord Healthcare Inc.'s mycophenolate mofetil under an ANDA. The approval updates the generic p…
-
CLINICAL_TRIALS research · 2024-07-23Clinical Trial Update: Cardiac Transplant Metabolomics With and Without Rejection
Clinical trial update on metabolomics in heart transplant recipients comparing with and without rejection. The study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-05-30Clinical Trial Update: Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
This clinical trial update reports on using intra-graft targeted gene expression profiling to diagnose heart allograft rejection. The trial …
-
FDA approval · 2024-05-21FDA Approved: CYCLOSPORINE — Original Application (Devatis Inc.)
FDA approved Devatis Inc.'s cyclosporine as a generic drug under an original ANDA (ANDA209811).
-
CLINICAL_TRIALS research · 2024-05-07Clinical Trial Update: Impact of SGLT2 Inhibitors in Heart Transplant Recipients [Phase 2]
Phase 2 trial assessing the impact of SGLT2 inhibitors in heart transplant recipients, investigating effects on heart failure, cardiac allog…
-
FDA approval · 2024-02-20FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for a generic version of mycophenolate mofetil (Aurobindo Pharma Limited) to prevent organ transplant …
-
FDA approval · 2024-01-25FDA Approved: TACROLIMUS — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved TACROLIMUS under Original Application from Amneal Pharmaceuticals NY LLC, including standard and extended-release capsule formu…
-
FDA approval · 2024-01-05FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for mycophenolate mofetil from Aurobindo Pharma Limited, authorizing the generic immunosuppressant for…
-
FDA approval · 2024-01-03FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' supplemental application for mycophenolate mofetil (ANDA 091249).
-
FDA approval · 2023-11-29FDA Approved: MYCOPHENOLIC ACID — Original Application (Biocon Pharma Inc.)
FDA approved mycophenolic acid from Biocon Pharma Inc. via an original application. It is indicated to prevent organ transplant rejection in…
-
FDA approval · 2023-09-14FDA Approved: ASTAGRAF XL — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for ASTAGRAF XL (tacrolimus extended-release capsules) from Astellas Pharma US, Inc.
-
FDA approval · 2023-06-22FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for mycophenolate mofetil filed by Meitheal Pharmaceuticals Inc. The approval relates to an addition…
-
FDA approval · 2023-06-22FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (ONESOURCE SPECIALTY PHARMA LIMITED)
FDA approved a supplemental application for mycophenolate mofetil submitted by Onesource Specialty Pharma Limited.
-
FDA approval · 2023-04-19FDA Approved: TACROLIMUS — Supplemental Application (Ascend Laboratories, LLC)
The FDA has approved a supplemental application for tacrolimus from Ascend Laboratories, LLC.
-
FDA approval · 2022-12-23FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (ONESOURCE SPECIALTY PHARMA LIMITED)
FDA approved an original application for mycophenolate mofetil, a generic immunosuppressant used to prevent organ transplant rejection.